The Origins of AIDS

by Pepin

  14. He N et al. The HIV epidemic in China: history, response, and challenge. Cell Res (2005), 15: 825–32.

  15. Ji G et al. Correlates of HIV infection among former blood/plasma donors in rural China. AIDS (2006), 20: 585–91.

  16. Ferguson J. Papa Doc, Baby Doc. Haiti and the Duvaliers. Oxford: Basil Blackwell, 1987.

  17. Severo R. Impoverished Haitians sell plasma for use in the US. New York Times, 28 January 1972.

  18. Abbott E. Haiti. The Duvaliers and their legacy. London: Robert Hale, 1988.

  19. Sapène R. Procès à Baby Doc. Paris: Philippe Daudy, 1973.

  20. Anonymous. Dynastic republicanism in Haiti. Polit Q (1973), 44: 77–84.

  21. Heinl RD et al. Written in blood. The story of the Haitian people 1492–1995. Lanham: University Press of America, 1996.

  22. Hagen PJ. Blood. Gift of merchandise. New York: Alan R Liss, 1982.

  23. Starr D. Blood. An epic history of medicine and commerce. New York: HarperCollins, 2002.

  24. Fortuné G. Haiti, une nation au service d’une minorité. Brussels: Éditions Vie Ouvrière, 1977.

  25. Anonymous. Haiti blood plasma curb poses problems. The Afro-American, 18 January 1973.

  26. Gold H. Best nightmare on Earth. A life in Haiti. New York: Prentice Hall Press, 1991.

  27. Deschamps MM et al. HIV infection in Haiti: natural history and disease progression. AIDS (2000), 14: 2515–21.

  28. Centers for Disease Control. Opportunistic infections and Kaposi’s sarcoma among Haitians in the United States. MMWR (1982), 31: 353–61.

  29. Vieira J et al. Opportunistic infections in previously healthy Haitian immigrants. N Eng J Med (1983), 308: 125–9.

  30. Moskowitz LB et al. Unusual cause of death in Haitians residing in Miami: high prevalence of opportunistic infections. JAMA (1983), 250: 1187–91.

  31. Malebranche R et al. Acquired immunodeficiencies syndrome with severe gastrointestinal manifestations in Haiti. Lancet (1983), 2: 873–8.

  32. Pitchenik A. Opportunistic infections and Kaposi’s sarcoma among Haitians: evidence of a new acquired immunodeficiency state. Ann Int Med (1983), 98: 277–84.

  33. Stanford JD. Spartacus international gay guide 1982. Amsterdam: Spartacus, 1982.

  34. Pape J et al. Characteristics of AIDS in Haiti. N Eng J Med (1983), 309: 945–50.

  35. Fischl M et al. An acquired immunodeficiency syndrome among Haitians: an update. Ann N Y Acad Sci (1984), 437: 325–33.

  36. Guerin JM et al. AIDS: specific aspects of the disease in Haiti. Ann N Y Acad Sci (1984), 437: 254–63.

  37. Pape J et al. The acquired immunodeficiency syndrome in Haiti. Ann Int Med (1985), 103: 674–8.

  38. The Collaborative Study Group of AIDS in Haitian-Americans: risk factors for AIDS among Haitians residing in the United States. JAMA (1987), 257: 635–9.

  39. Boulos R et al. HIV-1 in Haitian women, 1982–88. JAIDS (1990), 3: 721–8.

  40. Pape J et al. Prevalence of HIV infection and high-risk activities in Haiti. JAIDS (1990), 3: 995–1001.

  41. Farmer P. Infections and inequalities. The modern plagues. Berkeley: University of California Press, 1999.

  42. Desvarieux M et al. HIV and AIDS in Haiti: recent developments. AIDS Care (1991), 3: 271–9.

  43. Levine PH. HIV infection in hemophilia. J Clin Apher (1993), 8: 120–5.

  44. Levine OH. The acquired immunodeficiency syndrome in persons with hemophilia. Ann Int Med (1985), 103: 723–6.

  45. Kroner BL et al. HIV-1 infection incidence among persons with hemophilia in the United States and Western Europe, 1978–1990. JAIDS (1994), 7: 279–86.

  46. Cuthbert RJG et al. Five year prospective study of HIV infection in the Edinburgh haemophiliac cohort. Br Med J (1990), 301: 956–61.

  47. Fatkenheuer G et al. Marchands de sang. Lausanne: Pierre-Marcel Favre, 1986.

  48. World Health Organization. International plasma trafficking. Wkly Epidemiol Rec (2000), 75: 289–96.

  49. Kumar S. Austria investigates allegations of tainted-blood exports. Lancet (2000), 356: 920.

  50. Picard A. Blood trail: Canada still lacks controls on plasma trade, inquiry told. Toronto: Globe and Mail, 14 December 1995.

  51. Krever H. Commission of inquiry of the blood system in Canada. Final report. www.hc-sc.gc.ca/ahc-asc/activit/com/krever-eng.php.

  13 The globalisation

  1. Kawamura M. HIV-2 in West Africa in 1966. Lancet (1989), 1: 385.

  2. Dube DK et al. Serological and nucleic acid analyses for HIV and HTLV infection on archival human plasma samples from Zaire. Virology (1994), 202: 379–89.

  3. Wendler I et al. Seroepidemiology of HIV in Africa. Br Med J (1986), 293: 782–5.

  4. US Census Bureau. HIV/AIDS surveillance data base. Washington, 2006.

  5. Winkler E et al. Seroepidemiology of human retrovirus in Gabon. AIDS (1989), 3: 106–7.

  6. Merlin M et al. Surveillance épidémiologique du syndrome d’immunodépression acquise dans six états d’Afrique centrale. Med Trop (Mars) (1988), 48: 381–9.

  7. Clumeck N et al. Seroepidemiological studies of HLTV-III antibody prevalence among selected groups of heterosexual Africans. JAMA (1985), 254: 2599–602.

  8. Van de Perre P et al. Female prostitutes: a risk group for infection with HTLV-III. Lancet (1985), 2: 524–7.

  9. Vandersypen M. Femmes libres de Kigali. Cah Etud Afr (1977), 17: 95–120.

  10. Meheus A et al. Prevalence of gonorrhoea in prostitutes in a Central African town. Br J Vener Dis (1974), 50: 50–2.

  11. Larson A. Social context of HIV transmission in Africa: historical and cultural bases of East and Central African relations. Rev Infect Dis (1989), 11: 716–31.

  12. Vidal N et al. HIV type 1 diversity and antiretroviral drug resistance mutations in Burundi. AIDS Res Hum Retrovir (2007), 23: 175–80.

  13. Servais J et al. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda. AIDS Res Hum Retrovir (2004), 20: 279–83.

  14. Anonymous. HIV type 1 variation in World Health Organization sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. AIDS Res Hum Retrovir (1994), 10: 1327–43.

  15. Nzila N et al. The prevalence of infection with HIV over a 10-year period in rural Zaire. N Eng J Med (1988), 318: 276–9.

  16. Pepin J et al. The impact of HIV infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. Am J Trop Med Hyg (1992), 47: 133–40.

  17. Green S et al. Stable seroprevalence of HIV-1 infection in pregnancy in rural Zaire. AIDS (1994), 8: 397–8.

  18. Mokili JL et al. Genetic heterogeneity of HIV-1 subtypes in Kimpese, rural Democratic Republic of Congo. AIDS Res Hum Retrovir (1999), 15: 655–64.

  19. Vidal N et al. Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002. JAIDS (2005), 40: 456–62.

  20. Gray RR et al. Spatial phylodynamics of HIV-1 epidemic emergence in East Africa. AIDS (2009): F9–F17.

  21. Dalai SC et al. Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe. AIDS (2009), 23: 2523–32.

  22. Glynn J et al. The development of the HIV epidemic in Karonga district, Malawi. AIDS (2001), 15: 2025–9.

  23. McCormak G et al. Early evolution of the HIV type 1 subtype C epidemic in rural Malawi. J Virol (2002), 76: 12890–9.

  24. Robertson C. Women in the urban economy. In Hay MJ and Stichter S (eds.), African women south of the Sahara. London: Longman, 1984.

  25. Zehender G. Population dynamics of HIV-1 subtype B in a cohort of men-having-sex-with-men in Rome, Italy. JAIDS (2010), 55: 156–60.

  26. Brunet JB et al. Epidemiological aspects of AIDS in France. Ann N Y Acad Sci (1984), 437: 334–9.

  27. Hué S et al. Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups
. Proc Natl Acad Sci U S A (2005), 102: 4425–9.

  28. Picard A. The gift of death. Confronting Canada’s tainted blood tragedy. Toronto: HarperCollins, 1998.

  29. Lukashov VV et al. Evidence for HIV-1 strain of US intravenous drug users as founders of AIDS epidemic among intravenous drug users in northern Europe. AIDS Res Hum Retrovir (1996), 12: 1179–83.

  30. Thomson M. Increasing HIV-1 genetic diversity in Europe. Clin Infect Dis (2007), 196: 1120–4.

  31. Paraskevis D et al. Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin. Clin Infect Dis (2007), 196: 1167–76.

  32. Dietrich U et al. HIV-1 strains from India are highly divergent from prototypic African and US/European strains, but are linked to a South African isolate. AIDS (1993), 7: 23–7.

  33. Lakhashe S et al. HIV infection in India: epidemiology, molecular epidemiology and pathogenesis. J Biosc (2008), 33: 515–25.

  34. Grez M et al. Genetic analysis of HIV-1 and HIV-2 mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses. J Virol (1994), 68: 2161–8.

  35. Bredell H et al. Genetic characterization of HIV-1 from migrant workers in three South African gold mines. AIDS Res Hum Retrovir (1998), 14: 677–84.

  36. Jain MK et al. Epidemiology of HIV and AIDS in India. AIDS (1994), 8(suppl 2): S61–S75.

  37. Beyrer C et al. Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS (2000), 14: 75–83.

  38. Weninger BG et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS (1991), 5(suppl 2): S71–S85.

  39. Hemelaar J et al. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS (2006), 20: W13–W23.

  40. Liao H et al. Phylodynamic analysis of the dissemination of HIV-1 CRF01_AE in Vietnam. Virology (2009), 391: 51–6.

  41. Li Y et al. Explosive HIV-1 subtype B epidemics in Asia driven by geographic and risk group founder events. Virology (2010), 402: 223–7.

  42. Deng X et al. The epidemic origin and molecular properties of B’: a founder strain of the HIV-1 transmission in Asia. AIDS (2008), 22: 1851–64.

  43. Ligon-Borden BL. Dr Jonathan Mann: champion of human rights in the fight against AIDS. Sem Pediatr Infect Dis (2003), 14: 314–22.

  44. Fee E et al. Jonathan Mann, HIV/AIDS, and human rights. J Public Health Policy (2008), 29: 54–71.

  45. Camus A. La peste. Paris: Gallimard, 1947.

  46. Cohen J. The rise and fall of Projet Sida. Science (1997), 278: 1565–8.

  47. Ryder RW. Tribute to Jonathan Mann. AIDS (1998), 12: ii–v.

  48. Mann J et al. AIDS in the world. A global report. Harvard University Press, 1992.

  49. Mann J et al. AIDS in the world II. Oxford University Press, 1996.

  50. Tarantola D et al. Jonathan Mann: founder of the health and human rights movement. Am J Public Health (2006), 96: 1942–3.

  14 Assembling the puzzle

  1. Neel C et al. Molecular epidemiology of simian immunodeficiency virus infection in wild-living gorillas. J Virol (2010), 84: 1464–76.

  2. Wolfe N et al. Exposure to nonhuman primates in rural Cameroon. Emerg Infect Dis (2004), 10: 2094–9.

  3. Sautter G. Notes sur la construction du chemin de fer Congo–Océan (1921–1934). Cah Etud Afr (1967), 7: 219–99.

  4. Mathers BM et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008), 372: 1733–45.

  5. Muller-Trutwin M et al. Increase of HIV-1 subtype A in Central African Republic. JAIDS (1999), 21: 164–71.

  6. Vidal N et al. High genetic diversity of HIV-1 strains in Chad, West Central Africa. JAIDS (2003), 33: 239–46.

  7. Butler I et al. HIV genetic diversity: biological and public health consequences. Curr HIV Res (2007), 5: 23–45.

  8. Peeters M et al. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS (2003), 17: 2547–60.

  9. Vidal N et al. Unprecedented degree of HIV-1 group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J Virol (2000), 74: 10498–507.

  10. Kalish M et al. Recombinant viruses and early global HIV-1 epidemic. Emerg Infect Dis (2004), 10: 1227–34.

  11. Zhu T et al. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature (1998), 391: 594–7.

  12. Worobey M et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature (2008), 55: 661–4.

  13. Sonnet J et al. Early AIDS cases originating from Zaire and Burundi (1962–1976). Scand J Infect Dis (1987), 19: 511–17.

  14. Desmyter J et al. Anti LAV-HTLV-III in Kinshasa mothers in 1970 and 1980. Paris: International Conference on AIDS, June 1985.

  15. Merlin M et al. Surveillance épidémiologique du syndrome d’immunodépression acquise dans six états d’Afrique centrale. Med Trop (Mars) (1988), 48: 381–9.

  16. Infor-Congo. Congo Belge et Rwanda-Urundi. Guide du voyageur. Brussels: Office de l’Information et des Relations Publiques pour le Congo Belge et le Rwanda-Urundi, 1958.

  17. Beheyt P. Contribution à l’étude des hépatites en Afrique. L’hépatite épidémique et l’hépatite par inoculation. Ann Soc Bel Med Trop (1953), 33: 297–340.

  18. La Fontaine JS. City politics. A study of Léopoldville, 1962–63. Cambridge University Press, 1970.

  19. Raymaekers P. L’organisation des zones de squatting. Élément de résorption du chômage structurel dans les milieux urbains des pays en voie de développement. Application au milieu urbain de Léopoldville. Paris: Éditions Universitaires, 1964.

  20. Comhaire-Sylvain S. Femmes de Kinshasa, hier et aujourd’hui. Paris: Mouton, 1968.

  21. Illiffe J. The African AIDS epidemic. A history. Athens: Ohio University Press, 2006.

  22. US Census Bureau. HIV/AIDS surveillance data base. Washington, 2006.

  23. Boulos R et al. HIV-1 in Haitian women, 1982–88. JAIDS (1990), 3: 721–8.

  24. Jacquez J et al. Role of the primary infection in epidemics of HIV infection in gay cohorts. JAIDS (1994), 7: 1169–84.

  25. Byers R et al. Estimating AIDS infection rates in the San Francisco cohort. AIDS (1988), 2: 207–10.

  26. Foley B et al. Apparent founder effect during the early years of the San Francisco HIV-1 epidemic (1978–79). AIDS Res Hum Retrovir (2000), 15: 1463–9.

  27. Moore JD et al. HTLV-III seropositivity in 1971–72 parenteral drug abusers – a case of false positives or evidence of viral exposure. N Eng J Med (1986), 314: 1387–8.

  28. Des Jarlais DC. Risk reduction for AIDS among intravenous drug users. Ann Int Med (1985), 103: 755–9.

  29. Garrett L. The coming plague. Newly emerging diseases in a world out of balance. New York: Penguin Books, 1994.

  30. Bacchetti P et al. Incubation period of AIDS in San Francisco. Nature (1989), 338: 251–3.

  31. Busch MP et al. Risk of HIV transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion (1991), 31: 4–11.

  32. Kroner BL et al. HIV-1 infection incidence among persons with hemophilia in the United States and Western Europe, 1978–1990. JAIDS (1994), 7: 279–86.

  33. Goedert JJ et al. A prospective study of HIV-1 infection and the development of AIDS in subjects with hemophilia. N Eng J Med (1989), 321: 1141–8.

  34. Evatt BL et al. Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Eng J Med (1985), 312: 483–6.

  35. Lee CA. The best of times, the worst of times: a story of haemophilia. Clin Med (2009), 5: 453–8.

  36. Shilts R. And the band played on. Politics, people and the AIDS epidemic. New York: Penguin Books, 1987.

  37. Holtgrave DR et al. Updated annual transmission rates in the United States, 1977–2006. JAIDS (2009), 50: 236–8.

  Appendix Class
ification of retroviruses

  For readers unfamiliar with virology, this section reviews a few concepts, which are summarised in the table. HIV-1 and HIV-2 are the two human ‘retroviruses’ that cause AIDS. To replicate, retroviruses transcribe RNA into DNA, which is then integrated into the DNA genome of the human host cells. This process is the reverse of what normally happens (DNA transcripted into RNA), hence their name. Retroviruses are further subdivided into ‘lentiviruses’ (HIV-1 and HIV-2), ‘oncoviruses’ (HTLV-I, the first retrovirus isolated from humans, which does not cause AIDS but sometimes cancer or paraplegia) and ‘spumaviruses’ (not pathogenic).